Cargando…

Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma

This study aimed to evaluate whether the therapeutic switch from a formulation of Bimatoprost 0.1 mg/mL with benzalkonium chloride (BAK) or Bimatoprost 0.3 mg/mL preservative-free to a formulation of Bimatoprost 0.1 mg/mL preservative-free could improve eye surface conditions in patients with glauco...

Descripción completa

Detalles Bibliográficos
Autores principales: Filippelli, Mariaelena, Campagna, Giuseppe, Ciampa, Nicola, Fioretto, Gaetano, Giannini, Roberta, Marino, Pier Franco, dell’Omo, Roberto, Costagliola, Ciro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224644/
https://www.ncbi.nlm.nih.gov/pubmed/35743588
http://dx.doi.org/10.3390/jcm11123518
_version_ 1784733418899111936
author Filippelli, Mariaelena
Campagna, Giuseppe
Ciampa, Nicola
Fioretto, Gaetano
Giannini, Roberta
Marino, Pier Franco
dell’Omo, Roberto
Costagliola, Ciro
author_facet Filippelli, Mariaelena
Campagna, Giuseppe
Ciampa, Nicola
Fioretto, Gaetano
Giannini, Roberta
Marino, Pier Franco
dell’Omo, Roberto
Costagliola, Ciro
author_sort Filippelli, Mariaelena
collection PubMed
description This study aimed to evaluate whether the therapeutic switch from a formulation of Bimatoprost 0.1 mg/mL with benzalkonium chloride (BAK) or Bimatoprost 0.3 mg/mL preservative-free to a formulation of Bimatoprost 0.1 mg/mL preservative-free could improve eye surface conditions in patients with glaucoma; intraocular pressure (IOP) was also evaluated. All patients meeting the inclusion criteria were eligible for the therapeutic switch to Bimatoprost 0.1 mg/mL preservative-free. At each check visit, enrolled patients underwent a break-up time (BUT) test, an ocular surface disease index (OSDI) test, and a three-point tonometric curve. A total of 40 patients were enrolled (23 were in therapy with Bimatoprost 0.1 mg/mL with BAK and 17 with Bimatoprost 0.3 mg/mL preservative-free). Significant differences of OSDI and BUT between Bimatoprost 0.1 mg/mL with BAK at baseline vs. Bimatoprost 0.1 mg/mL preservative-free at 14 and 28 days (p < 0.0001 and p = 0.0003, respectively) were recorded. Similarly, significant differences of OSDI and BUT between Bimatoprost 0.3 mg/mL preservative-free at baseline vs. Bimatoprost 0.1 mg/mL preservative-free at 14 and 28 days (p < 0.0001 for both) were found. Bimatoprost 0.1 mg/mL preservative-free has a better tolerability profile associated with non-therapeutical inferiority in the control of IOP compared to the other Bimatoprost formulations.
format Online
Article
Text
id pubmed-9224644
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92246442022-06-24 Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma Filippelli, Mariaelena Campagna, Giuseppe Ciampa, Nicola Fioretto, Gaetano Giannini, Roberta Marino, Pier Franco dell’Omo, Roberto Costagliola, Ciro J Clin Med Article This study aimed to evaluate whether the therapeutic switch from a formulation of Bimatoprost 0.1 mg/mL with benzalkonium chloride (BAK) or Bimatoprost 0.3 mg/mL preservative-free to a formulation of Bimatoprost 0.1 mg/mL preservative-free could improve eye surface conditions in patients with glaucoma; intraocular pressure (IOP) was also evaluated. All patients meeting the inclusion criteria were eligible for the therapeutic switch to Bimatoprost 0.1 mg/mL preservative-free. At each check visit, enrolled patients underwent a break-up time (BUT) test, an ocular surface disease index (OSDI) test, and a three-point tonometric curve. A total of 40 patients were enrolled (23 were in therapy with Bimatoprost 0.1 mg/mL with BAK and 17 with Bimatoprost 0.3 mg/mL preservative-free). Significant differences of OSDI and BUT between Bimatoprost 0.1 mg/mL with BAK at baseline vs. Bimatoprost 0.1 mg/mL preservative-free at 14 and 28 days (p < 0.0001 and p = 0.0003, respectively) were recorded. Similarly, significant differences of OSDI and BUT between Bimatoprost 0.3 mg/mL preservative-free at baseline vs. Bimatoprost 0.1 mg/mL preservative-free at 14 and 28 days (p < 0.0001 for both) were found. Bimatoprost 0.1 mg/mL preservative-free has a better tolerability profile associated with non-therapeutical inferiority in the control of IOP compared to the other Bimatoprost formulations. MDPI 2022-06-19 /pmc/articles/PMC9224644/ /pubmed/35743588 http://dx.doi.org/10.3390/jcm11123518 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Filippelli, Mariaelena
Campagna, Giuseppe
Ciampa, Nicola
Fioretto, Gaetano
Giannini, Roberta
Marino, Pier Franco
dell’Omo, Roberto
Costagliola, Ciro
Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma
title Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma
title_full Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma
title_fullStr Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma
title_full_unstemmed Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma
title_short Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma
title_sort ocular tolerability of bimatoprost 0.1 mg/ml preservative-free versus bimatoprost 0.1 mg/ml with benzalkonium chloride or bimatoprost 0.3 mg/ml preservative-free in patients with primary open-angle glaucoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224644/
https://www.ncbi.nlm.nih.gov/pubmed/35743588
http://dx.doi.org/10.3390/jcm11123518
work_keys_str_mv AT filippellimariaelena oculartolerabilityofbimatoprost01mgmlpreservativefreeversusbimatoprost01mgmlwithbenzalkoniumchlorideorbimatoprost03mgmlpreservativefreeinpatientswithprimaryopenangleglaucoma
AT campagnagiuseppe oculartolerabilityofbimatoprost01mgmlpreservativefreeversusbimatoprost01mgmlwithbenzalkoniumchlorideorbimatoprost03mgmlpreservativefreeinpatientswithprimaryopenangleglaucoma
AT ciampanicola oculartolerabilityofbimatoprost01mgmlpreservativefreeversusbimatoprost01mgmlwithbenzalkoniumchlorideorbimatoprost03mgmlpreservativefreeinpatientswithprimaryopenangleglaucoma
AT fiorettogaetano oculartolerabilityofbimatoprost01mgmlpreservativefreeversusbimatoprost01mgmlwithbenzalkoniumchlorideorbimatoprost03mgmlpreservativefreeinpatientswithprimaryopenangleglaucoma
AT gianniniroberta oculartolerabilityofbimatoprost01mgmlpreservativefreeversusbimatoprost01mgmlwithbenzalkoniumchlorideorbimatoprost03mgmlpreservativefreeinpatientswithprimaryopenangleglaucoma
AT marinopierfranco oculartolerabilityofbimatoprost01mgmlpreservativefreeversusbimatoprost01mgmlwithbenzalkoniumchlorideorbimatoprost03mgmlpreservativefreeinpatientswithprimaryopenangleglaucoma
AT dellomoroberto oculartolerabilityofbimatoprost01mgmlpreservativefreeversusbimatoprost01mgmlwithbenzalkoniumchlorideorbimatoprost03mgmlpreservativefreeinpatientswithprimaryopenangleglaucoma
AT costagliolaciro oculartolerabilityofbimatoprost01mgmlpreservativefreeversusbimatoprost01mgmlwithbenzalkoniumchlorideorbimatoprost03mgmlpreservativefreeinpatientswithprimaryopenangleglaucoma